Giuseppe L Banna - JoVE Visualize

Showing results (41-50 of 42) with videos related to

Pageof 5

Sort By:

You have reached the last page of results.This site can display upto 42 results.

Cancer Immunology, Immunotherapy : CII|June 1, 2020

Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50Alessio Cortellini, Marcello Tiseo, Giuseppe L Banna, et al.

Journal for Immunotherapy of Cancer|September 29, 2025

Transformer-based AI approach to unravel long-term, time-dependent prognostic complexity in patients with advanced NSCLC and PD-L1 ≥50%: insights from the pembrolizumab 5-year global registryAlessio Cortellini, Valentina Santo, Leonardo Brunetti, et al.

Pageof 5

Showing results (41-50 of 42) with videos related to

Sort By:

Pageof 5

You have reached the last page of results.This site can display upto 42 results.

Cancer Immunology, Immunotherapy : CII|June 1, 2020

Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50Alessio Cortellini, Marcello Tiseo, Giuseppe L Banna, et al.

Journal for Immunotherapy of Cancer|September 29, 2025

Transformer-based AI approach to unravel long-term, time-dependent prognostic complexity in patients with advanced NSCLC and PD-L1 ≥50%: insights from the pembrolizumab 5-year global registryAlessio Cortellini, Valentina Santo, Leonardo Brunetti, et al.

Pageof 5